Another prospective randomized clinical trial in adults demonstrated that subcutaneous administration of insulin glargine within the first 12 hours of intravenous insulin infusion significantly decreased rebound hyperglycemia after discontinuation of intravenous insulin, with no adverse effects. This evidence concerns the gene INS and Hyperglycemia.